中文摘要：

目的 探讨CD13＋CD4＋CD25hi调节性T细胞（Treg细胞）在弥漫大B细胞淋巴瘤（DLBCL）患者外周血中的表达水平及其临床意义.方法 采用流式细胞术检测58例初诊DLBCL患者及30名健康对照者外周血CD13＋CD4＋CD25hi Treg细胞亚群在Treg细胞中的表达水平,并分析其与各临床指标的关系.结果 初诊DLBCL患者外周血CD13＋CD4＋CD25hi Treg细胞的表达高于健康对照者,两者差异有统计学意义[（36.37±11.89）%比（9.03±2.10）%,t=7.168,P＜0.001].国际预后指数（IPI）评分3~5分的初诊DLBCL患者外周血CD13＋CD4＋CD25hi Treg细胞表达水平高于0~2分的患者,两者差异有统计学意义[（44.28±10.10）%比（21.51±6.23）%,t=ˉ9.347,P=0.03].Ⅱ、Ⅲ、Ⅳ期DLBCL患者外周血CD13＋CD4＋CD25hi Treg细胞表达水平分别为（19.48±1.34）%、（33.98±8.03）%、（47.89±8.25）%,三者差异有统计学意义（F=38.363,P＜0.001）.而不同年龄、性别、乳酸脱氢酶（LDH）水平患者之间外周血CD13＋CD4＋CD25hi Treg细胞表达水平差异均无统计学意义（均P＞0.05）.结论 CD13＋CD4＋CD25hi Treg细胞亚群在DLBCL患者外周血中的表达水平明显升高,并与患者临床分期及预后相关.

英文摘要：

Objective To analyze the expression of peripheral blood CD13＋CD4＋CD25hi regulatory T cells （Treg cells） in patients with diffuse large B-cell lymphoma （DLBCL） and its clinical significance. Methods The expression of peripheral blood CD13＋CD4＋CD25hi Treg cells in 58 newly diagnosed patients with DLBCL and 30 healthy adults was detected by flow cytometry, and the relationship between its expression and the clinical indicators were analyzed statistically. Results The levels of peripheral blood CD13＋CD4＋CD25hi Treg cells in newly diagnosed DLBCL and healthy adults were different, with statistically significant difference [（36.37 ±11.89） % vs. （9.03 ±2.10） %, t = 7.168, P ＆lt; 0.001]. The level of peripheral blood CD13＋CD4＋CD25hi Treg cells was significantly higher in patients with IPI score 3ˉ5 than that in patients with IPI score 0ˉ2[（44.28±10.10）%vs. （21.51±6.23）%, t=ˉ9.347, P=0.03]. The expression of peripheral blood CD13＋ CD4＋ CD25hi Treg cells in stages Ⅱ, Ⅲ and Ⅳ patients were （19.48 ±1.34） %, （33.98 ±8.03） % and （47.89±8.25） %respectively, and there were significant differences among three groups （F= 38.363, P〈0.001）. The levels of peripheral blood CD13＋CD4＋CD25hi Treg cells had no relationship with age, sex or LDH level （all P〉0.05）. Conclusion The levels of peripheral blood CD13＋CD4＋CD25hi Treg cells are higher in DLBCL patients, which has a close relationship between the expression of CD13＋CD4＋CD25hi Treg cells and clinical stage and prognosis.